Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539684 | 1.00 | GSK3B (0.43) | GSK3BPTPN1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14822500 | 0.79 | P4HA1 (0.59) | MEN1KMT2AL3MBTL1CNR2 | |
| SCHEMBL30590918 | 0.79 | P4HA1 (0.59) | MEN1KMT2AL3MBTL1CNR2 | |
| SCHEMBL29317443 | 0.78 | HSD17B3 (0.49) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL31665026 | 0.77 | NNMT (0.53) | MEN1KMT2AL3MBTL1CNR2HPGDS | |
| SCHEMBL26107981 | 0.77 | MEN1 (0.43) | MEN1KMT2AL3MBTL1CNR2PDK1 | |
| SCHEMBL18397152 | 0.77 | GSK3B (0.39) | GSK3BPTPN1 | |
| SCHEMBL18397093 | 0.77 | MEN1 (0.43) | MEN1KMT2AL3MBTL1CNR2PDK1 | |
| SCHEMBL29539403 | 0.77 | MEN1 (0.43) | MEN1KMT2AL3MBTL1CNR2PDK1 | |
| SCHEMBL18296201 | 0.77 | NNMT (0.53) | MEN1KMT2AL3MBTL1CNR2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-116323582-A | Heteroaromatic ring compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2022-12-15 | — | — | US | disclosed |
| CN-107922396-B | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION (US) | 2022-03-15 | — | — | US | disclosed |
| US-20190016707-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION | 2019-01-17 | — | — | US | disclosed |
| EP-3325471-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | Genzyme Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015267-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274108-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885PTPN1 1491/4885MEN1 1440/4885 |
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | CYP2D6, CYP3A7, CYP2F1 | GSK3B 2647/4885PTPN1 4047/4885MEN1 948/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885PTPN1 1491/4885MEN1 1440/4885 |
| US-20220396588-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885PTPN1 1491/4885MEN1 1440/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | GSK3B 3153/4885PTPN1 609/4885MEN1 1446/4885 |
| US-20190016707-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | GSK3B 3571/4885PTPN1 1491/4885MEN1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.